Given the low intracranial response rates to either modality, ongoing trials are evaluating the efficacy of combining PD-1/PD-L1 blockade and chemotherapy in treatment-naïve NSCLC with BrMs. Here, PDCD1 is linked to non-small cell lung carcinoma.